These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 19025355)

  • 1. Molecular markers relating to malignant progression in Grade II astrocytoma.
    Yue WY; Yu SH; Zhao SG; Chen ZP
    J Neurosurg; 2009 Apr; 110(4):709-14. PubMed ID: 19025355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoexpression of tumor suppressor genes p53, p21 WAF1/CIP1 and p27 KIP1 in humam astrocystic tumors.
    Faria MH; Patrocínio RM; Moraes Filho MO; Rabenhorst SH
    Arq Neuropsiquiatr; 2007 Dec; 65(4B):1114-22. PubMed ID: 18345413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitosin and pHH3 predict poorer survival in astrocytomas WHO grades II and III.
    Varughese RK; Lind-Landström T; Habberstad AH; Salvesen Ø; Haug CS; Sundstrøm S; Torp SH
    J Clin Pathol; 2016 Jan; 69(1):26-34. PubMed ID: 26188054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysis.
    Ständer M; Peraud A; Leroch B; Kreth FW
    Cancer; 2004 Sep; 101(5):1028-35. PubMed ID: 15329912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CDC25B, Ki-67, and p53 expressions in reactive gliosis and astrocytomas.
    Suren D; Isiksacan Ozen O
    J BUON; 2013; 18(4):1006-11. PubMed ID: 24344030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas.
    Peraud A; Kreth FW; Wiestler OD; Kleihues P; Reulen HJ
    Clin Cancer Res; 2002 May; 8(5):1117-24. PubMed ID: 12006527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21(Waf1/Cip1) and p27(Kip1) in urothelial carcinoma: correlation with other cell-cycle-related proteins (Rb, p53, Ki-67 and PCNA) and clinicopathological features.
    Ioachim E; Michael M; Stavropoulos NE; Kitsiou E; Hastazeris K; Salmas M; Stefanaki S; Agnantis NJ
    Urol Int; 2004; 73(1):65-73. PubMed ID: 15263796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term molecular changes in WHO grade II astrocytomas following radiotherapy.
    Yue WY; Sai K; Wu QL; Xia YF; Yu SH; Chen ZP
    Chin J Cancer; 2012 Mar; 31(3):159-65. PubMed ID: 22313596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of gemistocytes in astrocytoma progression.
    Watanabe K; Tachibana O; Yonekawa Y; Kleihues P; Ohgaki H
    Lab Invest; 1997 Feb; 76(2):277-84. PubMed ID: 9042164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic and prognostic significance of cyclin A expression in low-grade astrocytomas: comparison with astrogliosis and high-grade tumours.
    Hara A; Saegusa M; Ichinoe M; Okayasu I
    J Clin Pathol; 2008 Mar; 61(3):287-92. PubMed ID: 18156430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 mutation, expression, and DNA ploidy in evolving gliomas: evidence for two pathways of progression.
    van Meyel DJ; Ramsay DA; Casson AG; Keeney M; Chambers AF; Cairncross JG
    J Natl Cancer Inst; 1994 Jul; 86(13):1011-7. PubMed ID: 8007011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies.
    Watanabe K; Sato K; Biernat W; Tachibana O; von Ammon K; Ogata N; Yonekawa Y; Kleihues P; Ohgaki H
    Clin Cancer Res; 1997 Apr; 3(4):523-30. PubMed ID: 9815715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathologic, immunohistochemical, and molecular features of benign and malignant phyllodes tumors of the breast.
    Kleer CG; Giordano TJ; Braun T; Oberman HA
    Mod Pathol; 2001 Mar; 14(3):185-90. PubMed ID: 11266524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue thioredoxin reductase-1 expression in astrocytomas of different grades.
    Esen H; Erdi F; Kaya B; Feyzioglu B; Keskin F; Demir LS
    J Neurooncol; 2015 Feb; 121(3):451-8. PubMed ID: 25391969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of molecular markers in low-grade diffuse astrocytomas: loss of p16 and retinoblastoma protein expression is associated with short survival.
    Hilton DA; Penney M; Evans B; Sanders H; Love S
    Am J Surg Pathol; 2002 Apr; 26(4):472-8. PubMed ID: 11914625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The significance of immunohistochemical expression of Ki-67, p53, p21, and p16 in meningiomas tissue arrays.
    Terzi A; Saglam EA; Barak A; Soylemezoglu F
    Pathol Res Pract; 2008; 204(5):305-14. PubMed ID: 18374497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrent astrocytic tumours--a study of p53 immunoreactivity and malignant progression.
    Sarkar C; Ralte AM; Sharma MC; Mehta VS
    Br J Neurosurg; 2002 Aug; 16(4):335-42. PubMed ID: 12389885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Analysis of PCNA, Ki67, AgNOR and p53 expression in brain glial tumors].
    Berny W; Weiser A; Markowska-Woyciechowska A; Jarmundowicz W; Zub W; Załuski R
    Neurol Neurochir Pol; 2004; 38(6):457-63. PubMed ID: 15654669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: relationships and prognostic value.
    Cunningham JM; Kimmel DW; Scheithauer BW; O'Fallon JR; Novotny PJ; Jenkins RB
    J Neurosurg; 1997 Jan; 86(1):121-30. PubMed ID: 8988090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cells with TP53 mutations in low grade astrocytic tumors evolve clonally to malignancy and are an unfavorable prognostic factor.
    Ishii N; Tada M; Hamou MF; Janzer RC; Meagher-Villemure K; Wiestler OD; Tribolet N; Van Meir EG
    Oncogene; 1999 Oct; 18(43):5870-8. PubMed ID: 10557074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.